Advertisement

Treatment of Refractory and Relapsed Acute Leukemias with Cytosine Arabinoside and Mitoxantrone

  • T. Rozmyslowicz
  • G. Palynyczko
  • J. Mazur
  • R. Konecki
  • D. Apel
  • B. Mariańska
  • S. Maj
  • J. Holowiecki
  • E. Rudzka
  • T. Ławniczek
  • ł Kachel
  • J. Wojnar
  • S. Krzemień
  • L. Konopka
  • S. Pawelski
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

In the last few years several new agents for the treatment of acute leukemia have been studied. These have included amsacrine, idarubicin, mitoxantrone, homoharringtonine and most recently diaziquone [1]. Mitoxantrone is a relatively new synthetic anthracenedione derivative with strong antineoplastic activity in vitro and in vivo against solid tumors and leukemias [2].

Keywords

Acute Leukemia Partial Remission Acute Myelogenous Leukemia Complete Remission Rate Cytosine Arabinoside 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arlin ZA (1990) Current status of mitoxantrone combination chemotherapy programs: a personal view. Leukemia Lymphoma 1: 301–305PubMedCrossRefGoogle Scholar
  2. 2.
    Durr FE, Wallace RE, Citarella RV (1983) Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 10 [Suppl B]: 3–11PubMedCrossRefGoogle Scholar
  3. 3.
    Rozmyslowicz T, Palynyczko G, Mazur J, Konopka L (1991) Mitoxantrone in the treatment of malignant haematological disorders (in Polish). Terapia i Leki 10: 255–262Google Scholar
  4. 4.
    Dalton WS, Cress AE, Alberts DS (1988) Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 48: 1882–1888PubMedGoogle Scholar
  5. 5.
    Alberts DS, Peng Y-P, Leigh S et al. (1983) Disposition of mitoxantrone in patients. Cancer Treat Rev 10 [Suppl B]: 23–27PubMedCrossRefGoogle Scholar
  6. 6.
    Benjamin RS, Chawla SP, Ewer MS et al. (1985) Evaluation of mitoxantrone cardiotoxicity by nuclear angiography and endomyocardial biopsy: an update. Invest New Drugs 3: 117–121PubMedCrossRefGoogle Scholar
  7. 7.
    Arlin ZA, Silver R, Cassileth Pet al. (1985) Phase I—II trial of mitoxantrone in acute leukaemia. Cancer Treat Rep 69: 61–64PubMedGoogle Scholar
  8. 8.
    Arlin ZA, Dukart G, Schoch I et al. (1985) Phase I—II trial of mitoxantrone in acute leukemia: interim report. Invest New drugs 3: 213–217PubMedCrossRefGoogle Scholar
  9. 9.
    Paciucci P, Dutcher J, Cuttner J et al. (1987) Mitoxantrone and Ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1 (7): 565–567PubMedGoogle Scholar
  10. 10.
    Hiddemann W, Kreutzmann H, Straif K et al. (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute leukemia. Blood 69: 744–749PubMedGoogle Scholar
  11. 11.
    Rozmyslowicz T, Palynyczko G, Mazur J et al. (1990) Mitoxantrone in treatment of refractory acute leukemias. Blood 76 (10) [Suppl 1]: 315aGoogle Scholar
  12. 12.
    Arlin ZA, Case D, Moore J et al. (1988) Randomized trial of mitoxantrone and daunorubicin-based therapy in untreated acute myelogenous leukemia. Am Soc Clin Oncol 7: 186Google Scholar
  13. 13.
    Hiddemann W, Büchner T, Heil G et al. (1990) Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 4 (9): 637–640PubMedGoogle Scholar
  14. 14.
    Kantarijan HM, Walters RL, Keating MJ et al. (1990) Mitoxantrone and high-dose arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 65: 5–8CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • T. Rozmyslowicz
    • 1
  • G. Palynyczko
    • 1
  • J. Mazur
    • 1
  • R. Konecki
    • 1
  • D. Apel
    • 1
  • B. Mariańska
    • 1
  • S. Maj
    • 1
  • J. Holowiecki
    • 2
  • E. Rudzka
    • 2
  • T. Ławniczek
    • 2
  • ł Kachel
    • 2
  • J. Wojnar
    • 2
  • S. Krzemień
    • 2
  • L. Konopka
    • 1
  • S. Pawelski
    • 1
  1. 1.Institute of HematologyWarsawPoland
  2. 2.Department of HematologyMedical AcademyKatowicePoland

Personalised recommendations